|
Dec 14
|
Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC)
|
|
Dec 12
|
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
|
|
Dec 11
|
Blueprint Medicines' (NASDAQ:BPMC) investors will be pleased with their respectable 63% return over the last year
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|
|
Dec 9
|
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
|
|
Dec 7
|
Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?
|
|
Dec 6
|
Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?
|
|
Dec 4
|
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 1
|
Why Is Glaxo (GSK) Up 5.3% Since Last Earnings Report?
|
|
Nov 30
|
Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?
|
|
Nov 29
|
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?
|
|
Nov 28
|
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
|
|
Sep 30
|
Director Jeffrey Albers Sells 25,000 Shares of Blueprint Medicines Corp
|